Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Galectin Therapeutics in a research report issued to clients and investors on Friday, August 16th. HC Wainwright analyst E. Arce expects that the company will earn ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.53) EPS and FY2027 earnings at $1.29 EPS.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04).
View Our Latest Analysis on GALT
Galectin Therapeutics Trading Down 2.1 %
NASDAQ GALT opened at $2.30 on Monday. The firm has a market capitalization of $142.94 million, a P/E ratio of -3.11 and a beta of 0.63. The business has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.55. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27.
Institutional Investors Weigh In On Galectin Therapeutics
Several large investors have recently made changes to their positions in GALT. Solutions 4 Wealth Ltd purchased a new stake in shares of Galectin Therapeutics during the 4th quarter valued at $60,000. Retirement Guys Formula LLC increased its position in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock valued at $81,000 after purchasing an additional 12,232 shares during the last quarter. Wealthspire Advisors LLC increased its holdings in Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock worth $952,000 after acquiring an additional 214,512 shares during the last quarter. Vanguard Group Inc. increased its holdings in Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after acquiring an additional 38,037 shares during the last quarter. Finally, Traynor Capital Management Inc. increased its holdings in Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock worth $97,000 after acquiring an additional 8,164 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Further Reading
- Five stocks we like better than Galectin Therapeutics
- How to Find Undervalued Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is an Earnings Surprise?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- 3 Ways To Invest In Coffee, Other Than Drinking It
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.